Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10146528 | 0.79 | PARP1 (0.56) | PARP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL8872733 | 0.76 | PARP1 (0.41) | PARP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14175140 | 0.76 | PARP1 (0.41) | PARP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4283192 | 0.76 | ESR1 (0.41) | PARP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5679402 | 0.76 | NUDT1 (0.51) | PARP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14958067 | 0.76 | MEN1 (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10807592 | 0.74 | GAA (0.35) | HSD17B10RPS6KA3KDM4EALDH1A1HTT | |
| SCHEMBL4363219 | 0.73 | GAA (0.43) | PARP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL10248315 | 0.73 | PARP1 (0.39) | PARP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL20687495 | 0.72 | MGAM (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| US-4772619-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0242341-A1 | Benzimidazoles, process for their preparation and preparations containing same | Aktiebolaget Hässle (SE) | 1987-10-21 | — | — | EP | disclosed |
| WO-1987005021-A1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | Aktiebolaget Hässle (SE) | 1987-08-27 | — | — | WO | disclosed |
| US-4508905-A | GASTRIC ACID SECRETION INHIBITORS | AKTIEBOLAGET HASSLE (SE) | 1985-04-02 | — | — | US | disclosed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | disclosed |
| US-4337257-A | Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion | AKTIEBOLAGET HASSLE (SE) | 1982-06-29 | — | — | US | disclosed |
| EP-0005129-B1 | SUBSTITUTED PYRIDYLSULFINYLBENZIMIDAZOLES HAVING GASTRIC ACID SECRETION PROPERTIES, PHARMACEUTICAL PREPARATIONS CONTAINING SAME, AND INTERMEDIATES FOR THEIR PREPARATION | Aktiebolaget Hässle (SE) | 1981-04-29 | — | — | EP | disclosed |
| US-4255431-A | Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion | AKTIEBOLAGET HASSLE (SE) | 1981-03-10 | — | — | US | disclosed |
| EP-0005129-A1 | Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation | Aktiebolaget Hässle (SE) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | PARP1 2912/4885HSD17B10 954/4885GRIN2D 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.